Seeking Alpha

Actavis settles patent suit

  • Actavis (ACT) and Noven Pharmaceuticals agree to settle all outstanding patent litigation related to the former's generic version of Daytrana (Methylphenidate Transdermal System), a CNS stimulant used to treat ADHD.
  • Noven grants Actavis a non-exclusive royalty-bearing license to market its generic Daytrana beginning September 1, 2015 contingent on ACT receiving FDA approval for the drug.
  • 2013 Daytrana sales in the U.S. were $98M.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio: